+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Anastomosis Devices Market Report is set to have rapid growth due the rising surgical procedures along with growing incidence of cardiovascular and gastrointestinal diseases at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Anastomosis Devices Market Report : Forecast By Product (Disposable, Reusable), By Application (Cardiovascular Surgery, Gastrointestinal Surgery), By Region, Competitive Landscape, and Segment Forecasts.

The global Anastomosis Devices market is poised for rapid growth between 2019 and 2029. The increase in the number of cardiovascular surgical procedures performed and an increase in the prevalence of chronic diseases, such as gastrointestinal and cardiac disorders, are the main factors driving the global market for anastomotic devices worldwide.

According to the European Commission, about 181,000 bypass anastomoses for heart revascularization procedures were performed in the 25 EU Member States in 2016. Among them, Germany conducted about 51,000 cardiac bypass operations in 2016. This will probably fuel the demand of anastomotic devices in the near future.

Furthermore, rapid technological progress is expected to be a favorable reimbursement scenario for cardiac procedures, including coronary artery bypass grafting (CABG), open heart valve replacement and angioplasty, in regions developed for encourage the adoption of anastomotic devices during the forecast period. However, the complications associated with anastomosis, such as anastomotic leaks, are expected to hamper the global market for anastomotic devices.

Leading companies featured in the report include Medtronic; LivaNova PLC; MAQUET Holding B.V. & Co. KG.; Dextera Surgical Inc.; Vitalitec Internaional Inc.; Synovis Micro Companies Alliance, Inc.; and Ethicon US, LLC.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read